PSUSA/00009145/202412

Human medicines European public assessment report (EPAR): Kisqali, ribociclib, Date of authorisation: 22/08/2017, Revision: 23, Status: Authorised

Human medicines European public assessment report (EPAR): Lutathera, lutetium (177Lu) oxodotreotide, Date of authorisation: 26/09/2017, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Iclusig, ponatinib, Date of authorisation: 01/07/2013, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR): Kaftrio, ivacaftor,tezacaftor,elexacaftor, Date of authorisation: 21/08/2020, Revision: 31, Status: Authorised

Human medicines European public assessment report (EPAR): Eyluxvi, aflibercept, Date of authorisation: 15/09/2025, Status: Authorised

Meeting of the Medicine Shortages Single Point of Contact (SPOC) Working Party, Online, from 11 November 2025, 09:30 (CET) to 11 November 2025, 13:00 (CET)

Human medicines European public assessment report (EPAR): Glivec, imatinib, Date of authorisation: 07/11/2001, Revision: 51, Status: Authorised

EVVet3 EVWeb Production - Release notes

List of eligible industry stakeholder organisations